Clinical Trials
2
Active:0
Completed:0
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Virogin Biotech Canada Ltd
- Target Recruit Count
- 12
- Registration Number
- NCT05266612
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸MD Anderson, Houston, Texas, United States
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Phase 2
Recruiting
- Conditions
- Intrahepatic CholangiocarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Virogin Biotech Canada Ltd
- Target Recruit Count
- 97
- Registration Number
- NCT05223816
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
News
No news found